Estamos no ar no ! Saiba mais
ícone de UTHR

United Therapeutics
UTHR

533,12 USD
-8,39
1,55%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
533,12
0,00
0%
1 dia
-1,55%
5 dias
-3,68%
1 mês
6,95%
3 meses
0,77%
6 meses
-8,16%
No acumulado do ano
7,33%
1 ano
23,21%
5 anos
189,24%
10 anos
353,72%
 

Sobre: United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Funcionários: 1.400

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 40,4%
Neutro 51,1%
Negativo 8,5%
Neutro
Zacks Investment Research
anteontem
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Positivo
Proactive Investors
anteontem
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Neutro
Zacks Investment Research
anteontem
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Positivo
24/7 Wall Street
anteontem
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Positivo
Zacks Investment Research
anteontem
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Positivo
Investors Business Daily
anteontem
Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed
Liquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.
Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed
Neutro
Business Wire
há 3 dias
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc.
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
Positivo
Zacks Investment Research
há 7 dias
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Negativo
Zacks Investment Research
há 15 dias
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Positivo
Benzinga
há 15 dias
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™